Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes
Status:
Completed
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether exenatide is superior to insulin glargine
(after 24 weeks) in reducing liver fat content (by MRS) in patients with newly diagnosed type
2 diabetes mellitus and concomitant non-alcoholic fatty-liver disease(NAFLD).